Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?

• Autors principals: Yuqian Feng (Autor), Huimin Jin (Autor), Kaibo Guo (Autor), Yuying Xiang (Autor), Yiting Zhang (Autor), Wurong Du (Autor), Minhe Shen (Autor), Shanming Ruan (Autor)
• Format: Llibre
• Publicat: Frontiers Media S.A., 2021-02-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Background: Combination therapy with immune checkpoint inhibitors (ICIs) has been widely used for clinical treatment in recent years, which has a better survival benefit. However, not all patients can derive clinical benefit from combination immunotherapy. Therefore, it is necessary to explore the b...